Lung Cancer
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
Article
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
Conference Coverage
Lung cancer: Proton beam radiotherapy likely reduces cardiovascular events
A retrospective study shows lower rates of transient ischemic attack and MI with proton beam radiotherapy.
News
One-month delay in cancer treatment linked to increase in mortality
The risk of death varied by treatment type.
Clinical Topics & News
Guideline Concordance with Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience
A retrospective review of use of durvalumab use among patients with NSCLC found that just one-third of eligible veteran patients actually received...
News
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Single and multifraction SBRT found comparable for lung metastases
A single-fraction regimen and a four-fraction regimen netted essentially the same toxicity and oncologic outcomes at 1 year of follow-up.
News
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
Conference Coverage
Lower BP and better tumor control with drug combo?
Conference Coverage
National lung cancer screening guidelines may miss younger African American individuals at high risk
Retrospective analysis finds many lung cancer patients would not have counted as eligible for low-dose CT under guidelines that are being...
